Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia?

Canadian Journal of Cardiology

Volumn 23, Issue 6, 2007, Pages 467-473

  Grover, Steven A ^a,b   Coupal, Louis ^a,b   Kaouache, Mohammed ^a,b   Lowensteyn, Ilka ^a,b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Hypertension; Lipids; Prevention

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; DIABETES MELLITUS; DISEASE FREE INTERVAL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL; TREATMENT DURATION; ADOLESCENT; AGE DISTRIBUTION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; MIDDLE AGED; MORTALITY; PREVENTIVE HEALTH SERVICE; SEX RATIO;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CANADA; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DYSLIPIDEMIAS; FEMALE; HEALTH CARE COSTS; HEALTH SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVENTIVE HEALTH SERVICES; SEX DISTRIBUTION;

EID: 34250626095     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70786-9     Document Type: Article

References (30)

1. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada, 2003. Heart and Stroke Foundation of Canada, 2003. (Version current at March 19, 2007).
2. Health Canada. Economic burden of illness in Canada, 1998. Health Canada Publications, 2002. (Version current at March 19, 2007).
3. Khan NA, McAlister FA, Campbell NRC, et al; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2004;20:41-54.
4. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-4. (Erratum in 2003;169:1149).
5. MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian Heart Health Surveys: A profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:1969-74.
6. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-62. (Erratum in 1998;158:1228).
7. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: The Lipid Research Clinics Program prevalence study. Circulation 1980;61:302-15.
8. Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102:722-7.
9. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005;95:586-91.
10. Statistics Canada. Life tables: Canada, Provinces and Territories 1995-1997. [84-537-XIE]. Ottawa, Statistics Canada, 2002. (Version current at Match 19, 2007).
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;326:1427-34.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003;326:1423-7.
14. Statistics Canada. Population and growth components (1851-2001 censuses). Statistics Canada, 2005. (Version current at March 19, 2007).
15. Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: Importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006;166:213-9.
16. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1990;323:1301-7.
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acure coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
18. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.
19. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Med 1980;69:725-32.
20. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann NY Acad Sci 1978;304:267-92.
21. Smith WM. Treatment of mild hypertension: Results of a ten-year intervention trial. Circ Res 1977;40(Suppl 1):198-105.
22. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994;272:1932-8.
23. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-63.
24. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities study. Arch Intern Med 1995;155:677-84.
25. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999; 160:41-6.
26. Stephenson J. Noncompliance may cause half of antihypertensive drug "failures". JAMA 1999;282:313-4.
27. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
28. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/ Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997;277:1281-6.
29. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
30. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238-44.